Approval · Notice of Compliance 26831 · 2021
IMATINIB: Notice of Compliance 26831
Issued October 13, 2021
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 26831
- Date
- October 13, 2021
- Company
- Sivem Pharmaceuticals UlcSaint-Laurent, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Abbreviated New Drug Submission (ANDS)
- Submission class
- Labelling Only
- Reason
- Administrative: Licensing Agreement Between Two Companies
- Canadian reference product
- GLEEVEC (Novartis Pharmaceuticals Canada Inc.)
Products in this notice
Medicinal ingredients
- IMATINIB MESYLATE 400 MG per TAB
- IMATINIB MESYLATE 100 MG per TAB